In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Diabetes drug Tirzepatide, which is shown to be more effective than Wegovy and Ozempic, is likely to be approved by the Food and Drug Administration for weight loss in 2023 and is expected to be ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

Tirzepatide, a new drug that could have far-reaching impact — and billions in sales — is likely to be approved for weight loss by the Food and Drug Administration in 2023.

The Central Drug Standard Control Organization (CDSCO), the country's apex drug regulator, has approved to Eli Lilly's Tirzepatide. This is an active ingredient that is found in the pharmaceutical ...

If tirzepatide remains off the FDA's drug shortage list, compounding pharmacies must cease the production of these medications on any significant scale, according to gastroenterologist and obesity ...

Tirzepatide and semaglutide are type 2 diabetes drugs that are often used for weight loss. While tirzepatide may potentially be more effective, it's too early to know that based on current research.

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

Drugmaker Eli Lilly is hoping tirzepatide, sold as Mounjaro and Zepbound for diabetes and weight loss, will become the first drug approved to treat sleep apnea, which it says affects some 80 ...

The FDA is expected to approve tirzepatide for weight loss this year. Clinical trials found patients lost an average of 22.5% of their body weight on the drug. The drug is not expected to be ...